Analysis of Real-World Patients With Myeloma Who Have Extramedullary Disease
A retrospective analysis of myeloma patients with extramedullary disease provided insights into the characteristics that may influence outcomes.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Depressive Symptoms May Be Associated With Survival in Patients With Hematologic Malignancies
Patients with lymphoma or myeloma were assessed prior to and 1 month after initiating chemotherapy for depressive symptoms.
Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma
In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.
FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Prognostic Factors After Second Allogeneic HSCT in Patients With Relapsed Myelodysplastic Syndrome
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
Worse Prognosis for Patients Treated With Upfront Radiation Therapy for Multiple Myeloma
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
Darzalex Gets Approval for Additional Multiple Myeloma Indication
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Cardiovascular AEs Common With Carfilzomib in Multiple Myeloma
Patients with relapsed multiple myeloma experiencing CVAEs had inferior survival.
Recommendations Issued for Imaging Use in Multiple Myeloma
In a review published in the June 1 issue of The Lancet Oncology, recommendations are presented for use of newer imaging techniques for the diagnosis of multiple myeloma.
Smoldering Myeloma Risk Models Identified High-Risk Patients in the Real World
Several different models were found to be equally useful for predicting those at risk of progression in multiple myeloma.
Pneumococcal Vaccination Induces Antibody Responses in Patients With Multiple Myeloma
A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.
Addition of Daratumumab to Frontline Treatment May Improve Outcomes in Transplant-Eligible Patients With Multiple Myeloma
This is the first phase 3 to evaluate daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma.
Addition of Investigational mAb Isatuximab May Represent a New Treatment Option in Multiple Myeloma
This is the first phase 3 study evaluating the efficacy of adding a CD38 antibody to pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
ASCT Reduced the Risk of Early Relapse for Some Patients With Multiple Myeloma Receiving KRd
Chromosomal abnormalities and serum lactate dehydrogenase level are factors included in the revised international staging system (R-ISS) for multiple myeloma.
Subcutaneous Daratumumab Associated With Higher Patient Satisfaction, Drastically Fewer Infusion Reactions Than Intravenous Formulations
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Daratumumab Cuts Risk for Progression in Multiple Myeloma
For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death.
Lenalidomide Shown to Reduce the Risk of Progression in Smoldering Multiple Myeloma
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Age at Diagnosis of Myeloproliferative Neoplasm Affects Pattern of Thrombotic Events but Not Mortality Risk
A retrospective study compared disease progression and mortality rates in younger patients with MPNs vs historical controls of older patients with MPNs.
Imaging Studies Critical in Distinguishing Extramedullary Disease in Multiple Myeloma Diagnosis
This case illustrates the role of PET/CT imaging at diagnosis in determining extramedullary disease in patients with multiple myeloma.
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
